Eton Pharmaceuticals opened at $68.38, in line with its previous close of $68.40. In the last trading session, the stock traded between $62.31 and $69.05. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Eton Pharmaceuticals is now worth
$ 1,261.97
Giving a profit of
$ 1,161.97 (1161.97%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-6.94 (-10.15%)
Day High
$69.05
Day Low
$62.31
Day Open
$68.38
Prev Close
$68.40
Volume
9,05,651
1W Return
21.24%
1M Return
10.98%
3M Return
46.20%
6M Return
105.96%
1Y Return
248.01%
Market Cap ($ Mn)
1,773
PE Ratio
149.45
PB Ratio
36.30
PEG Ratio
-
ROE
-18.84%
ROCE
-1.45%
EPS (TTM)
$1.22
1 Week
21.24%
1 Month
10.98%
3 Months
46.20%
6 Months
105.96%
9 Months
282.92%
B. Riley maintains Buy on Eton Pharmaceuticals, raises target to $81
B. Riley Securities maintains a Buy rating on Eton Pharmaceuticals. Price target raised from $70 to $81 by analyst Madison El-Saadi. No change in the investment recommendation status.
2 days agoCanaccord Genuity raises Eton Pharmaceuticals price target to $80
Canaccord Genuity raised the price target for Eton Pharmaceuticals from $68 to $80. Analyst Gary Nachman maintained a Buy rating on the stock. The price target increase amounts to $12 per share.
6 days agoEton Pharmaceuticals Q3FY26 Results: Revenue up 158% to $57.9M
Revenue surged 158% YoY to $57.9 million, driven by Hemangiol. Adjusted EBITDA margin reached 49%, nearing the 50% target set for 2028. Net income swung to $35.2 million from a $1.9 million loss in prior year. Full-year 2026 revenue guidance raised to over $175 million.
7 days agoEton Pharmaceuticals launches IMPAVIDO for rare disease treatment in US
Eton Pharmaceuticals launched IMPAVIDO (miltefosine) capsules in the US on September 28, 2026. The company holds exclusive commercialization rights and integrates the drug into its rare disease portfolio. Eton Cares support includes $0 co-pay for eligible commercially insured patients. Distribution is centralized through Anovo Specialty Pharmacy for outpatient and inpatient access.
1mo agoEton Pharmaceuticals to host 1x1 meetings at Wells Fargo Healthcare Conference
Eton Pharmaceuticals will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference in Boston, MA. The conference runs September 8-10, 2026; meetings can be scheduled through Wells Fargo institutional sales representatives. The company currently has eleven commercial rare disease products, including IMPAVIDO with a September 2026 launch. Eton Pharmaceuticals has five product candidates in late-stage development, including ASN-001, AMGLIDIA, ET-700, ET-800, and ZENEO hydrocortisone autoinjector.
2mo agoEton Pharmaceuticals Q2 adj. EPS $0.43 beats $0.10 estimate
Eton Pharmaceuticals delivered a strong Q2 2026 performance, beating analyst estimates for both earnings and revenue. Adjusted EPS of $0.43 surpassed the $0.10 consensus by nearly 291%, while sales of $37.6 million exceeded the $27.1 million forecast. Driven by the Hemangiol relaunch, the company raised full-year revenue guidance to over $145 million.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Eton Pharmaceuticals is now worth
$ 1,261.97
Giving a profit of
$ 1,161.97 (1161.97%)
Note: Past profits do not guarantee future returns.
